1. Our details

This website is owned and operated by Inserm Transfert, Barbara Cagniard, Project Manager (Tel.: +33 1 55 03 01 04; Address: 7 Rue Watt, 75013 Paris, France)

  • Design & Programming: ML-Com, France
  • Hosting: OVH, 140 quai du Sartel, 59100 Roubaix, France, Phone: +33 899 701 761


2. Disclaimer

Inserm Transfert maintains this website to enhance public access to information about Ebovac2. Our goal is to keep this information timely and accurate. If errors are brought to our attention, we will try to correct them. However, Inserm Transfert accepts no responsibility or liability whatsoever with regard to the information on this site.

This information is:

  • of a general nature only and is not intended to address the specific circumstances of any particular individual or entity
  • not necessarily comprehensive, complete, accurate or up to date
  • sometimes linked to external sites over which Inserm Transfert have no control and for which Inserm Transfert assumes no responsibility

Ebovac2 is a research program. The content of this website is not intended to give medical diagnosis, treatment or medical advice.


3. Privacy policy

The site complies with the regulations on data processing, data files and individual liberties set out in the General Data Protection Regulation (EU Regulation 2016/679) (GDPR) and the French Data files and Individual Liberties defined by Law no. 78-17, as amended in the Privacy policy.


4. Copyright notice

All rights reserved.

This information may be freely used and copied for educational and other non-commercial purposes, provided that any reproduction of data be accompanied by an acknowledgement of Ebovac2 as the source (© Ebolavac2).
This does not apply to the pages and images with explicitly reserved reproduction right: © followed by the right owner and the year of first circulation. Reproduction of the latter requires prior authorization from the Ebovac2 for the pages.

News

  • 23 April 2019

    An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!

  • 24 September 2018

    The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi (Kenya) in January 2019. 

  • 17 January 2018

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018. For more information

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research